Embryonic stem cells |
RAD51 |
HRR |
[38] |
DNA-PKcs |
DSB |
[41] |
MSH2, MSH6 |
MMR |
[42] |
Hematopoietic stem cells (quiescent) |
|
NHEJ |
[45] |
Hematopoietic stem cells (proliferative) |
|
HRR |
[45] |
Normal multipotent stem cells from hair follicle bulge |
Bcl-2, p53 |
increase resistance DNA-damaged induced death |
[46] |
Keratinocyte stem cells |
FGF2 |
DBSR, SSBR |
[47] |
Glioma tumor-initiating cells |
CHK1, CHK2 |
Increase activation |
[51] |
BMI-1, DNA-PK, PARP-1 |
Repair IR-induced DNA damage |
[50] |
MGMT |
DSB, NHEJ |
[57] |
EZH2/HOX |
Alkylating agent sensitivity |
[61–63] |
|
PcG |
[64, 65] |
Breast cancer cell line MCF-7 |
RAD51, APE1 |
SSBR |
[70] |
AKT, WNT signaling |
Increased DNA repair |
[71, 72] |
p53-null Lin−CD29HCD24H
|
BRCA1 |
Increased Expression |
[73] |
Metastatic malignant melanoma |
|
Higher DNA repair |
[67–69] |
Pancreatic cancer |
BRCA1 |
BRCA1-mediated repair |
Unpublished, Mathews et al. |
|
RAD51 |
RAD51 DNA damage response |
[74] |